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Abstract
The key to understanding why certain indi-
viduals develop deep vein thrombosis at
varying times, despite similar risk factors be-
ing present, is the realization of the impor-
tance of gene-gene and gene-environment
interactions between risk factors. The discov-
ery of factor V Leiden and several other coag-
ulation abnormalities, which are now known
to be common in the general population, has
revolutionized the way in which the aetiology
of venous thrombosis is viewed. On the basis
of current knowledge, time-dependent mod-
els taking account of various forms of inter-
action have been developed.
Copyright© 1999 S Karger AG, Basel
Introduction
Thrombosis is a multicausal disease in-
volving a variety of risk factors, many of
which are common; it is now appreciated that
the interaction of multiple risk factors over
time determines the risk of thrombosis. It is
often overlooked in comparisons between
studies that one of the most important of
these risk factors is age. In individuals aged
less than 20 years, the incidence of venous
thrombosis is l per 100,000 people; at middle
age it is approximately l per l ,000, which is
also the overall incidence; thereafter it in-
creases steeply, and in old age approaches l %
per year.
Risk Factors
The risk factors for venous thrombosis are
now generally classified äs either genetic or
acquired (table 1).
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Egeberg [1], in 1965, was the first to estab-
lish a hereditary tendency to thrombosis when
he recorded an inherited antithrombin defi-
ciency within a family with thrombophilia. In
the early 1980s, deficiencies of two natural
anticoagulant proteins - protein C and pro-
tein S - were described in familial thrombo-
philia by Griffin et al. [2] and Schwartz et al.
[3], respectively. Over the last 5 years, a vari-
ety of coagulation abnormalities predisposing
to venous thrombosis have been identified.
The first of these, described in 1993 by Dahl-
bäck et al. [4], was a previously unrecognized
mechanism characterized by a poor anticoag-
ulant response to activated protein C (APC),
i.e. APC resistance. This was subsequently
shown by Bertina et al. [5] in 1994 to be
caused by a mutation in blood coagulation
factor V, otherwise known äs factor V Leiden.
Heterozygous deficiency of the three major
natural inhibitors of the procoagulant System
- protein C, protein S and antithrombin -
leads to excessive thrombin formation. Other
abnormalities leading to gains in function and
excesses in the procoagulant System include
mutation of the prothrombin (factor II) gene,
which is associated with raised plasma con-
centrations of prothrombin 2021OA and an
increased risk of thrombosis [6]. Raised con-
centrations of coagulation factor VIII, possi-
bly caused by subtle changes in the regulation
of gene activity [7], are also associated with an
increased risk of thrombosis [8].
Variation due to Acquired Factors
Apart from genetic considerations, varia-
tions in the risk of venous thrombosis might
also be explained by acquired factors or a
combination of both acquired and genetic fac-
tors. Hyperhomocysteinaemia, which has
been found to be associated with venous
thrombosis in a number of studies [9-12], is a
good example of abnormal plasma concentra-
tions resulting from both genetic and acquired
factors. It is also plausible that raised levels of
factor VIII and prothrombin reflect a combi-
nation of genetic and acquired factors.
Prevalence and Risk Estimates
Even among patients with thrombosis, de-
ficiencies of protein C, protein S and anti-
thrombin (the classical deficiencies) are rare.
Far more common in the general population
are APC resistance, prothrombin 2021 OA,
high concentrations of factor VIII, and hyper-
homocysteinaemia. As shown in table 2 [6,
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13-18], 5% of the population have APC resis-
tance äs a result of factor V Leiden [17, 19].
Factor V Leiden is restricted to Caucasians,
and regional differences are high. As shown in
the table, factor V Leiden occurs in 20% of
consecutive patients with venous thrombosis
[17, 20] and increases the risk of thrombosis
approximately eightfold among heterozygous
carriers [17]. Prothrombin 20210A appears to
be a relatively mild risk factor, increasing the
risk of thrombosis by two- to threefold [6].
Again, this mutation has largely been reported
in the white population [21]. Concentrations
of factor VIII exceeding 1,500 IU/1 have been
detected in 11 % of the general population and
in 25% of thrombotic patients; such levels are
associated with a sixfold increased risk of
thrombosis äs compared with concentrations
belowl,OOOIU/l[8].
The bürden of deep vein thrombosis in
society is largely explained by the latter four
abnormalities, each of which is associated
with a greater attributable risk than the three
classical deficiencies combined. The discov-
ery of factor V Leiden and an assessment of its
prevalence in unselected patients with deep
vein thrombosis (20%), patients with familial
thrombosis (50%) and in the general popula-
tion (5%) revolutionized the way in which the
aetiology of thrombosis was viewed. Now that
common risk factors had been identified, it
became clear that there must be individuals
having more than one risk factor. This realiza-
tion led to attention being diverted to issues of
selection and interaction.
Venous Thrombosis äs a Multicausal
Disorder
The demonstration that venous thrombo-
sis is a multicausal disorder is most obvious in
children. Although thrombosis is rare in chil-
dren, in the event of it occurring, a variety of
genetic and acquired risk factors are usually
present simultaneously [22, 23]. The multi-
causality of thrombosis is also true in adults.
In fact, for the development of thrombosis,
multiple risk factors are a prerequisite.
Selection and Interaction
Among families with thrombophilia,
thrombogenic abnormalities are far higher
than in the unselected patient with thrombo-
Venous Thrombosis. Prevalence and
Interaction of Risk Factors
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Table 3. Age at first thrombosis

















From [33], with permission.
sis. In families with thrombophilia, the main
coagulation inhibitors are deficient in 15% of
individuals, prothrombin 2021OA is evident
in nearly 20%, and factor V Leiden occurs in
40-60%. Members of these families are also
at higher risk for thrombosis than are other
individuals with similar defects [5, 16, 24-
29]. The most important determinant of an
individual's thrombotic risk when comparing
patients with the same defect appears to be
the way in which they are identified or select-
ed. Companson between consecutive unse-
lected patients and patients from families
with thrombophilia indicates a lower mean
age at first thrombosis for thrombophilic pa-
tients than for consecutive individuals with
thrombosis, regardless of the underlying de-
fect, äs shown in table 3 [30].
The severity of thrombotic disease is de-
fmed here äs the age at onset of the condition;
the more severe the thrombotic tendency, the
earlier the first thrombotic event occurs. Even
in thrombophilic families with no identifiable
defect, thrombosis occurs at an early age [31].
Why then does the same disorder with the
same molecular basis manifest itself with
greater severity in the thrombophilic popula-
tion than in the unselected population? An
explanation of this anomaly was found with
the discovery of factor V Leiden, some 10
years after initial studies with thrombophilic
patients had centred on the absence or pres-
ence of protein C deficiency. With the discov-
ery of factor V Leiden, and further studies in
familial thrombophilia, the role of gene-gene
interaction and its influence on thrombosis-
free survival became apparent.
Gene-Gene Interaction
It is now appreciated that although throm-
bosis is multicausal, in families with thrombo-
philia, it is also multigenic. That is, in each of
the families studied, there are a variety of
genetic defects. As shown in figure l, mem-
bers of families with thrombophilia were
found in early studies to be at a high risk of
thrombosis if they had protein C deficiency
compared with relatives who did not have the
deficiency [28]. Fifty percent of those rela-
tives with protein C deficiency had thrombo-
sis by the age of 50 years. This suggests that an
extremely high risk of thrombosis results from
a deficiency in protein C. Some years later,
these families were assessed for the newly dis-
covered factor V Leiden. The presence of fac-
tor V Leiden was found to be a common sec-
ondary defect in a high number of individuals
from these families. Further investigation re-
vealed that the risk of thrombosis was far
greater for those family members carrying
Haemostasis 1999 29(suppl 1)1-9 Rosendaal
Fig. 1. Thrombosis-free survival in
famihes with thrombophiha due to
protem C deficiency (proband ex-
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both defects than for those patients carrymg
protem C deficiency or factor V Leiden alone
[31]. From these findmgs it became clear that
the thrombosis nsk associated with protem C
had been previously overestimated
Gene-Environment Interaction
A stnkmg example of gene-environment
mteraction is that relating to the use of oral
contraceptives m the presence of factor V
Venous Thrombosis Prevalence and
Interaction of Risk Factors
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Fig. 2. Gene-environment interaction relating to the
use of oral contraceptives in the presence of factor V
Leiden.
Leiden, äs shown in figure 2. Among unselect-
ed patients, Vandenbroucke et al. [32] re-
vealed a synergistic effect between factor V
Leiden and the use of oral contraceptives. The
relative risk of thrombosis in women using
oral contraceptives and carrying factor V
Leiden was found to be 34.7, äs compared
with 6.9 for women not using oral contracep-
tives and carrying factor V Leiden. For wom-
en using oral contraceptives and not carrying
factor V Leiden, the relative risk of thrombo-
sis was 3.7.
Models of Thrombosis Risk
The need for a dynamic age-dependent
model allowing a variety of forms of interac-
tion of risk factors, such äs additive effects or
synergism, became evident when even the de-
velopment of multicausal models, incorporat-
ing genetic and acquired risk factors, failed to
readily explain why equal numbers of risk fac-
tors cause thrombosis in one individual and
not in another, or why the same set of risk fac-
tors do not cause thrombosis in children but
do so in older individuals. An example of a
dynamic age-dependent model of this sort is
shown in figure 3.
This model assumes that each risk factor
contributes to the risk of thrombosis - this is
referred to äs the subject's 'thrombosis poten-
tial'. In the figure, the black lines indicate the
thrombosis potential of each individual risk
factor, whereas the grey lines indicate the total
thrombosis potential of the individual. The
figure traces the progress of a woman with fac-
tor V Leiden throughout the course of various
events in her life. In the first panel, the risk
factors considered are age and factor V Lei-
den alone. Here, the thrombosis potential,
indicated by a black line, corresponds to that
when no other risk factors are encountered
throughout her life. The resultant overall life-
time thrombosis potential - following the in-
sertion of an intravenous catheter while a
child, the use of oral contraceptives between
the age of 20 and 40, and immobilization due
to a skiing accident at age 30 - follows a com-
plicated form, and will, äs a result of a combi-
nation of specific risk factors at a particular
age, exceed the thrombosis threshold (shown
äs a broken and dotted line). As shown in the
fifth panel of the figure, the thrombosis
threshold is exceeded in our scenario at the
age of 30 years, following immobilization,
and leads to deep vein thrombosis. It is im-
portant to emphasize here that exceeding the
threshold does not depend on the number of
risk factors present; this same set of risk fac-
tors would not have caused thrombosis at age
20. Alternatively, if the woman had not re-
quired a plaster cast, but had continued to
take oral contraceptives, thrombosis would
have occurred at about the age of 50. Finally,
at a greater age, the effect of age and factor V
Leiden alone would have been adequate to
lead to thrombosis.
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Risk factors Childhood disease
• Overall thrombosis potential
Use of oral contraceptives Skiing accident leads to immobilisation at age 30 years
Use of oral contraceptives
n






Deep-vein thrombosis at age 30 years
Deep-vein thrombosis at age 50 years with continued
use of oral contraceptives and at advanced age by
age factor V Leiden alone
Deep-vein thrombosis
Thrombosis thresrtold Thrombosis Ihreshold
Age - 30 years 50 years
Fig. 3. Models of thrombosis risk. From Rosendaal [33].
In the model described in figure 3, it is V Leiden and use of oral contraceptives are
assumed that all the risk factors considered taken into account. Here it can be seen that a
behave in an additive fashion, i.e. without different picture emerges regarding thrombo-
interaction. Figure 4 illustrates a refmed mod- sis potential if interactions of risk factors are
el in which the supra-additive effects of factor taken into account in this way.
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Fig. 4. Models of thrombosis risk
with different interactions between
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Conclusion
An important predisposing factor for ve-
nous thrombosis is age, and the disease is
characterized by an interaction between ge-
netic and acquired risk factors. Also of impor-
tance are gene-environment interactions. In-
dividual risk can be determined by a time-
dependent model in which interaction be-
tween risk factors is crucial. Such models
explain why thrombosis occurs in an individ-
ual at a specific time. In the future, such mod-
els may enable the tailoring of individual risk
profiles and enable guidelines to be set for
prevention and prophylaxis. However, to
achieve this, additional Information regard-
ing the combined effects of all possible combi-
nations of risk factors will be required.
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